
Evommune Inc (EVMN) Stock Forecast & Price Target
Evommune Inc (EVMN) Analyst Ratings
Bulls say
Evommune is a promising biotech company due to its focus on creating novel treatments for chronic inflammatory diseases, such as AD and UC. Despite a recent setback in one of its trials, the company's assets, EVO301 and EVO756, have shown potential in generating high sales and could greatly increase shareholder value. With a strong financial position and experienced management team, Evommune has the potential for long-term success in the growing AD market.
Bears say
Evommune is a biotech company with potential treatments for inflammatory diseases. While their lead candidates show promise in clinical trials, their stock outlook is negative due to potential risks and uncertainties. Upcoming data readouts and potential mergers and acquisitions could greatly impact their stock value, but significant setbacks have also been experienced in the past.
This aggregate rating is based on analysts' research of Evommune Inc and is not a guaranteed prediction by Public.com or investment advice.
Evommune Inc (EVMN) Analyst Forecast & Price Prediction
Start investing in Evommune Inc (EVMN)
Order type
Buy in
Order amount
Est. shares
0 shares